Dr. Dean Regier, PhD

Who we are:

Case study research allows for the identification of causal mechanisms underlying complex, systems-dependent phenomena-like innovation. However, determining that there is a causal effect does not provide the causal story.

Data governance in support of LHS initiatives for precision oncology implicates an intricate web of statutes, regulations, guidance, policies, and practices.

Precision oncology is premised on large-scale, annotated 'omics data that improve our understanding of mutations, treatment response, resistance, quality of life and side effects, within an LHS.

Confronted with value uncertainty and high patient demand, payers are considering managed access approaches that re-evaluate adopted technologies or that manage the risk of early patient access through risk-sharing arrangements between developers and healthcare systems.

Patients with advanced Hodgkin’s Lymphoma (HL) have been with the combination of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and have largely positive outcomes.

Stereotactic ablative radiotherapy (SABR) may offer potential benefit for patients with oligometastatic cancers. The SABR technology is still evolving, and there is still uncertainty about whether or not this treatment will be effective.

Detecting prostate cancer early in men at risk is of prostate cancer can potentially improve outcomes. Prostate specific antigen (PSA) testing, however, has been shown to not be an effective method of detecting prostate cancer in the population.

The PACER lab leads the health economics activities of this multi-year research project in collaboration with researchers from the Genome Sciences Centre and the Centre for Lymphoid Cancer.

The GeneSolve study, recently funded by Genome British Columbia, examines the value of genomic sequencing for diagnosing childhood rare diseases.

BC Cancer’s Personalized OncoGenomics (POG) Program is a world-leading initiative applying whole-genome and transcriptome analysis (WGTA) to inform real-time treatment decisions for patients with advanced, hard-to-treat cancers. Using a mixed methods approach, Dr.

As a co-investigator on this project and leader of the GE³LS research activities, Dr. Regier leads the health economics activities of the LSARP project.

The Silent Genomes project aims to elucidate and address the health inequities faced by Canadian Indigenous populations when accessing genomic technologies for the diagnosis of genetic diseases.

Dr. Regier’s GeneSolve study, recently funded by Genome British Columbia, examines the value of genomic sequencing for diagnosing childhood rare diseases.

BC Cancer’s Personalized OncoGenomics (POG) Program is a world-leading initiative applying whole-genome and transcriptome analysis (WGTA) to inform real-time treatment decisions for patients with advanced, hard-to-treat cancers. Dr.

Dr. Regier’s CIHR-funded Catalyst project applies a mixed methods approach to enhancing shared decision-making in context to the return of genetic test results for hereditary cancer syndromes.

The CIHR-funded Catalyst project applies a mixed methods approach to enhancing shared decision-making in context to the return of genetic test results for hereditary cancer syndromes.